乙肝散联合单磷酸阿糖腺苷治疗慢性乙型肝炎35例临床分析(英文)

The Clinical Analysis of 35 Cases of Chronic B-type Hepatitis with Yigansan Combined Arabinosydenosine Monophosphate

目的 :对中药制剂乙肝散联合单磷酸阿糖腺苷 (Ara Amp)治疗慢性乙型肝炎进行临床分析。方法 :随机分为治疗组(35例 )和对照组 (35例 )。乙肝散口服 9g/次 ,3次 /d ,连服 3个月 ;Ara Amp第 1～ 10天肌注 2次 /d ,2 0 0mg/次 ,第 11～ 5 0天肌注 1次 /d ,2 0 0mg/次 ,治疗组两药联用 ,对照组单用Ara Amp。结果 :血清病毒学指标方面 ,治疗组HBeAg阴转率 5 1% ,对照组 38% ,两组比较有显著差异 (P <0 0 5 ) ;治疗组HBV DNA阴转率 46 % ,对照组 41% ,两者无明显差异 (P >0 0 5 ) ;肝功能方面 ,两组均取得明显效果 ,组间比较无明显差异 (P >0 0 5 )。结论 :中药制剂乙肝散联合Ara Amp治疗慢性乙型肝炎 ,能明显改善肝功能 ,并提高HBeAg阴转率。

Objective:To analyse the treatment of chronic B type hepatitis with traditional Chinese medicine pharmaceutic Yigansan combined Arabinosydenosine monophosohate(Ara Amp).Methods:Eighty patients were divided into treatment group(35 cases)and control group(45 cases)at random.Yigansan was taken 9 grams each time,3 times a day,for 3 months in a course of treatment.Ara Amp was injected intramuscularly 200mg each time,2 times a day from the first day to the tenth day,and one time a day from the eleventh day to the fiftieth day.Treatment group was treated with both Yigansan and Ara Amp,and control group was treated with Ara Amp only.Results:On the respect of serum virology index,the conversion of HBeAg from positive to negative in treatment group and control group were 51%,38% respectively.And there was significant difference statistically between the two groups(P<0 05).The conversion of HBV DNA from positive to negative in treatment group and control group was 46%,41% respectively.And there was not significant difference between the two groups(P>0 05).On the respect of the function of liver,there was not significant difference between the two groups(P>0 05).Conclusion:Ara Amp combined traditional Chinese medicine pharmaceutics Yigansan can obviously improve the liver function of patients with chronic B type hepatitis and promote their conversion of HbeAg from positive to negative.